Oncolines B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oncolines B.V. - overview
Established
2021
Location
Oss, -, Netherlands
Primary Industry
Biotechnology
About
Based in Oss, Netherlands, and founded in 2021 by Guido Zaman, Oncolines B. V. operates as a biotechnology company that specializes in precision medicine for oncology and immunotherapy. In January 2023, Symeres, a portfolio company of Keensight Capital, acquired Oncolines B.
V. Oncolines B. V. provides precision medicine services that specialize in oncology and immunotherapy.
The company provides services such as bioinformatics analysis, gene mutation analysis, tissue sensitivity analysis, synergistic combination therapies, protein expression analysis, and mechanistic cell biology analysis to help clients bring improved and novel therapies to the right patient population. The firm's clients are biotech, pharmaceutical, and academic firms looking for differentiation for their drugs and drug candidates.
Current Investors
Symeres
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.oncolines.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Oncolines B.V. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Oncolines B.V. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.